Ari Chaouat
Overview
Explore the profile of Ari Chaouat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
3419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Benamron H, Chaouat A, Carpentier N, Jankowski R, Nguyen D
Acta Otolaryngol
. 2023 Jul;
143(7):606-609.
PMID: 37466358
No abstract available.
12.
Perez T, Roche N, Nunes H, Burgel P, Chaouat A, Surpas P, et al.
Respir Med
. 2023 Jul;
217:107309.
PMID: 37394196
Background And Aim: Few questionnaires are available for routine assessment of dyspnea. The study aimed to design a self-administered questionnaire assessing the impact of chronic dyspnea on daily activities, named...
13.
Thore P, Staentzel J, Valentin S, Guillaumot A, Selton-Suty C, Gomez E, et al.
Respir Med Res
. 2023 Apr;
83:101008.
PMID: 37087904
Background: Pulmonary hypertension (PH) is a hemodynamic condition characterized by an abnormal elevation in pulmonary arterial pressures. Several pathophysiological pre-capillary and post-capillary mechanisms have been described. PH is a common...
14.
Jais X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al.
Lancet Respir Med
. 2022 Aug;
10(10):961-971.
PMID: 35926542
Background: Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised controlled trials comparing these treatments are lacking. We aimed to evaluate...
15.
Lacasse Y, Casaburi R, Sliwinski P, Chaouat A, Fletcher E, Haidl P, et al.
Lancet Respir Med
. 2022 Jul;
10(11):1029-1037.
PMID: 35817074
Background: Long-term oxygen therapy (LTOT) improves survival in patients with chronic obstructive pulmonary disease (COPD) and severe hypoxaemia. However, the best method of management of moderate hypoxaemia not qualifying for...
16.
Montani D, Lechartier B, Girerd B, Eyries M, Ghigna M, Savale L, et al.
Eur Respir J
. 2022 May;
60(6).
PMID: 35618278
Background: The phenotype of pulmonary arterial hypertension (PAH) patients carrying pathogenic variants remains mostly unknown. Methods: We report the genetic analysis findings, characteristics and outcomes of patients with heritable PAH...
17.
Valentin S, Renel B, Manneville F, Caron B, Choukour M, Guillaumot A, et al.
Inflamm Bowel Dis
. 2022 Apr;
29(2):207-216.
PMID: 35394504
Background: No large, prospective study has investigated respiratory symptoms in patients with inflammatory bowel diseases. We aimed to describe the prevalence of and factors associated with respiratory symptoms in patients...
18.
Lechartier B, Chaouat A, Aubert J, Schwitter J
Swiss Med Wkly
. 2022 Mar;
152:w30055.
PMID: 35262319
Pulmonary hypertension is an heterogeneous group of diseases characterised by increased pulmonary arterial pressures which impact on the upstream right ventricle. Pulmonary hypertension can be challenging to diagnose, classify and...
19.
Basin S, Valentin S, Maurac A, Poussel M, Pequignot B, Brindel A, et al.
Respir Med Res
. 2022 Jan;
81:100880.
PMID: 34974204
Rationale: Viral respiratory infections, including SARS-CoV-2 infection, can trigger respiratory symptoms among patients suffering from chronic respiratory diseases, leading to exacerbations and hospitalizations. Despite the tropism of SARS-CoV-2 into the...
20.
Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prevot G, et al.
Eur Respir J
. 2021 Nov;
59(6).
PMID: 34737227
Introduction: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate...